Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3973
Name thyroid gland medullary carcinoma
Definition A thyroid gland carcinoma that has_material_basis_in parafollicular cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland medullary carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RET C634W Sorafenib thyroid gland medullary carcinoma sensitive detail...
RET M918T Cabozantinib thyroid gland medullary carcinoma sensitive detail...
RET mutant Everolimus thyroid gland medullary carcinoma sensitive detail...
RET C620R Everolimus thyroid gland medullary carcinoma predicted - sensitive detail...
RET M918T Everolimus thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634W XMD15-44 thyroid gland medullary carcinoma sensitive detail...
RET C634W ALW-II-41-27 thyroid gland medullary carcinoma sensitive detail...
RET C634W HG-6-63-01 thyroid gland medullary carcinoma sensitive detail...
RET M918T HG-6-63-01 thyroid gland medullary carcinoma sensitive detail...
RET M918T XMD15-44 thyroid gland medullary carcinoma sensitive detail...
RET M918T ALW-II-41-27 thyroid gland medullary carcinoma sensitive detail...
RET positive Y078-DM4 thyroid gland medullary carcinoma sensitive detail...
RET M918T AZD1480 thyroid gland medullary carcinoma sensitive detail...
RET mutant Cabozantinib thyroid gland medullary carcinoma sensitive detail...
HRAS mutant Cabozantinib thyroid gland medullary carcinoma sensitive detail...
RET M918T Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634R Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634Y Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634F Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C618R Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
ATM L804fs ATM S978fs RET M918T Everolimus + Vandetanib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634W RXDX-105 thyroid gland medullary carcinoma sensitive detail...
RET C634W Pralsetinib thyroid gland medullary carcinoma sensitive detail...
RET C609X N/A thyroid gland medullary carcinoma not applicable detail...
RET C611X N/A thyroid gland medullary carcinoma not applicable detail...
RET C618X N/A thyroid gland medullary carcinoma not applicable detail...
RET C620X N/A thyroid gland medullary carcinoma not applicable detail...
RET C630X N/A thyroid gland medullary carcinoma not applicable detail...
RET C634X N/A thyroid gland medullary carcinoma not applicable detail...
RET A883X N/A thyroid gland medullary carcinoma not applicable detail...
RET M918X N/A thyroid gland medullary carcinoma not applicable detail...
RET V804M RET E805K N/A thyroid gland medullary carcinoma not applicable detail...
RET V804M RET Y806C N/A thyroid gland medullary carcinoma not applicable detail...
RET V804M RET S904C N/A thyroid gland medullary carcinoma not applicable detail...
RET E768X N/A thyroid gland medullary carcinoma not applicable detail...
RET L790X N/A thyroid gland medullary carcinoma not applicable detail...
RET Y791X N/A thyroid gland medullary carcinoma not applicable detail...
RET V804X N/A thyroid gland medullary carcinoma not applicable detail...
RET S891X N/A thyroid gland medullary carcinoma not applicable detail...
RET L629P RET D631_R635delinsG RET V637R Pralsetinib thyroid gland medullary carcinoma predicted - sensitive detail...
RET M918T Pralsetinib thyroid gland medullary carcinoma sensitive detail...
RET mutant Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET V804M Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET M918T Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET C634W Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET V804M RET M918T Everolimus + Vandetanib thyroid gland medullary carcinoma resistant detail...
RET V804M RET M918T Selpercatinib thyroid gland medullary carcinoma predicted - sensitive detail...
RET fusion Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET V804L Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET V804M RET G810S RET L881V RET M918T Selpercatinib thyroid gland medullary carcinoma predicted - resistant detail...
RET mutant Pralsetinib thyroid gland medullary carcinoma sensitive detail...
RET C634X Pralsetinib thyroid gland medullary carcinoma sensitive detail...
RET V804X Pralsetinib thyroid gland medullary carcinoma sensitive detail...
RET D378_G385delinsE Selpercatinib thyroid gland medullary carcinoma predicted - sensitive detail...
RET fusion Pralsetinib thyroid gland medullary carcinoma sensitive detail...
RET C634W Pz-1 thyroid gland medullary carcinoma sensitive detail...
RET M918T Pz-1 thyroid gland medullary carcinoma sensitive detail...
RET C634W SYHA1815 thyroid gland medullary carcinoma sensitive detail...
NRAS mutant Cabozantinib thyroid gland medullary carcinoma sensitive detail...
ALK rearrange Crizotinib thyroid gland medullary carcinoma predicted - sensitive detail...
RET E632_L633del Selpercatinib thyroid gland medullary carcinoma conflicting detail...
RET D631_L633delinsS Selpercatinib thyroid gland medullary carcinoma predicted - sensitive detail...
RET V591_G607del RET L1016S Pralsetinib thyroid gland medullary carcinoma predicted - sensitive detail...
MLH1 negative Pembrolizumab thyroid gland medullary carcinoma sensitive detail...
PMS2 negative Pembrolizumab thyroid gland medullary carcinoma sensitive detail...
MSH2 negative Pembrolizumab thyroid gland medullary carcinoma sensitive detail...
MSH6 negative Pembrolizumab thyroid gland medullary carcinoma sensitive detail...
RET D898_E901del Vandetanib thyroid gland medullary carcinoma predicted - resistant detail...
RET D898_E901del Selpercatinib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634W Vepafestinib thyroid gland medullary carcinoma sensitive detail...
RET Y806C RET M918T Pralsetinib thyroid gland medullary carcinoma predicted - resistant detail...
RET Y806C RET M918T Selpercatinib thyroid gland medullary carcinoma predicted - resistant detail...
RET G810N RET M918T Selpercatinib thyroid gland medullary carcinoma predicted - resistant detail...
HRAS A59T RET A883F RET A883T Pralsetinib thyroid gland medullary carcinoma predicted - resistant detail...
RET S891A Vandetanib thyroid gland medullary carcinoma predicted - sensitive detail...
EML4 - ALK Crizotinib thyroid gland medullary carcinoma predicted - sensitive detail...
RET L633_A639del Vandetanib thyroid gland medullary carcinoma predicted - sensitive detail...
RET D378_G385delinsE Vandetanib thyroid gland medullary carcinoma predicted - sensitive detail...
RET M918T MitoQ + Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET C634W MitoQ + Selpercatinib thyroid gland medullary carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT01838642 Phase II Ponatinib Ponatinib for Advanced Medullary Thyroid Cancer Terminated USA 0
NCT01896479 FDA approved Cabozantinib A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) Active, not recruiting ITA | FRA | ESP | CAN | AUS 9
NCT02657551 Phase II Regorafenib A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer Active, not recruiting USA 0
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL 6
NCT03072160 Phase II Pembrolizumab Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer Completed USA 0
NCT03157128 Phase Ib/II Selpercatinib A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT03753919 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) Active, not recruiting ESP 0
NCT03780517 Phase I DS-5010 Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Completed USA | FRA | ESP | BEL 3
NCT03838692 Phase II Ponatinib Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Withdrawn 0
NCT04106843 Phase II lutetium Lu 177 dotatate Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Withdrawn USA 0
NCT04211337 Phase III Vandetanib Cabozantinib Selpercatinib A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 12
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Recruiting USA | GBR | CAN 1
NCT04759911 Phase II Selpercatinib Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Recruiting USA 0
NCT04760288 Phase III Cabozantinib Pralsetinib Vandetanib A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC) Withdrawn ESP 0
NCT05241834 Phase I LOXO-260 A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment Recruiting USA 0